Gemtuzumab ozogamicin
DrugBank ID: DB00056
Summary
| Metric | Value |
|---|---|
| Total Predictions | 50 |
| KG+DL (Dual Validated) | 15 |
| DL Only | 35 |
| KG Only | 0 |
Predictions
| Indication | Score | Source |
|---|---|---|
| acute myeloid leukemia with t(8;21)(q22;q22) translocation | 0.9849 | KG+DL |
| acute myeloid leukemia with CEBPA somatic mutations | 0.9838 | KG+DL |
| acute myeloid leukemia with inv3(p21;q26.2) or t(3;3)(p21;q26.2) | 0.9834 | KG+DL |
| Richter syndrome | 0.9806 | DL |
| bulbar polio | 0.9792 | DL |
| chronic myelogenous leukemia, BCR-ABL1 positive | 0.9789 | DL |
| metastatic neoplasm | 0.9726 | DL |
| malignant spiradenoma | 0.9723 | DL |
| 5q35 microduplication syndrome | 0.9716 | DL |
| myeloid leukemia | 0.9702 | KG+DL |
| acute myeloid leukemia with t(8;16)(p11;p13) translocation | 0.9654 | KG+DL |
| acute myeloid leukemia with t(9;11)(p22;q23) | 0.9619 | KG+DL |
| acute myeloid leukemia and myelodysplastic syndromes related to topoisomerase type 2 inhibitor | 0.9594 | KG+DL |
| acute myeloid leukemia with t(6;9)(p23;q34) | 0.9588 | KG+DL |
| therapy related acute myeloid leukemia and myelodysplastic syndrome | 0.9579 | KG+DL |
| neuralgic amyotrophy | 0.9574 | DL |
| amyotrophic neuralgia | 0.9540 | DL |
| acute myeloid leukemia with minimal differentiation | 0.9526 | KG+DL |
| inherited acute myeloid leukemia | 0.9518 | KG+DL |
| acute lymphoblastic/lymphocytic leukemia | 0.9509 | DL |
| unclassified acute myeloid leukemia | 0.9461 | KG+DL |
| acute myeloblastic leukemia with maturation | 0.9399 | KG+DL |
| acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent | 0.9386 | DL |
| acute myeloid leukemia and myelodysplastic syndromes related to radiation | 0.9386 | DL |
| acute myeloid leukemia with NPM1 somatic mutations | 0.9386 | KG+DL |
| chronic lymphocytic leukemia/small lymphocytic lymphoma with immunoglobulin heavy chain variable-region gene somatic hypermutation | 0.9344 | DL |
| pregerminal center chronic lymphocytic leukemia/small lymphocytic lymphoma | 0.9344 | DL |
| polyclonal hypergammaglobulinemia | 0.9326 | DL |
| acute myeloblastic leukemia without maturation | 0.9305 | KG+DL |
| familial thrombocytosis | 0.9265 | DL |
| myelodysplastic/myeloproliferative disease | 0.9249 | DL |
| monoclonal paraproteinemia disease | 0.9199 | DL |
| acute panmyelosis with myelofibrosis | 0.9161 | DL |
| reactive thrombocytosis | 0.9079 | DL |
| chronic lymphocytic leukemia/small lymphocytic lymphoma | 0.8876 | DL |
| bilineal acute myeloid leukemia | 0.8753 | DL |
| metastatic melanoma | 0.8753 | DL |
| non-cutaneous melanoma | 0.8712 | DL |
| epithelioid cell melanoma | 0.8642 | DL |
| eyelid melanoma | 0.8630 | DL |
| scrotum melanoma | 0.8544 | DL |
| inverse Klippel-Trenaunay syndrome | 0.8515 | DL |
| blast phase chronic myelogenous leukemia, BCR-ABL1 positive | 0.8461 | DL |
| CDK4 linked melanoma | 0.8414 | DL |
| acral lentiginous melanoma (disease) | 0.8414 | DL |
| amelanotic skin melanoma | 0.8414 | DL |
| balloon cell malignant melanoma | 0.8414 | DL |
| lentigo maligna melanoma | 0.8414 | DL |
| malignant melanoma of the mucosa | 0.8414 | DL |
| superficial spreading melanoma | 0.8414 | DL |
External Links
Disclaimer
Predictions are for research purposes only and do not constitute medical advice.
Predictions are for research purposes only and do not constitute medical advice.